Press Release : New data for Roche's Hemlibra -2-

[1] Jiménez-Yuste J, et al. Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with factor (F)VIII Inhibitors. Presented at: International Society on Thrombosis and Haemostasis (ISTH) Congress; 2021 Jul 17-21; Philadelphia, PA, USA. Abstract PB0521.

[2] Oldenburg J, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017; 377:809-818.

[3] Young G, et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood. 2018; 132 (Supplement 1): 632.

[4] Pipe S, et al. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors: Results from the phase 3 HAVEN 4 study. Presented at: WFH World Congress; 2018 May 20-24; Glasgow, Scotland, UK. Abstract M-LBMED01-005 (854).

[5] Srivastava, A, Santagostino, E, Dougall, A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020: 26 (Suppl 6): 1--158.

[6] Carcao M, Goudemand J., Inhibitors in hemophilia: a primer. 5th ed. Montreal: World Federation of Hemophilia; 2018

[7] Iorio A et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med. 2019 Oct 15;171(8):540-546.

[8] Franchini M, et al. Haemophilia A in the third millennium. Blood Rev. 2013; 179-84.

[9] Gomez K, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014; 12:s319-s329.

[10] Whelan SF, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of haemophilia A patients. Blood. 2013; 121:1039-48.

Roche Group Media Relations

Phone: [phone] / e-mail: [e-mail] https://www.globenewswire.com/Tracker?data=G0cC-QgcCI9CVzVA9t_f1cTPkGOLsmG_05Cl8RQYvxqhDKdHIxg9LQ3dPxdUJ-PiFjEMRMt2iPqy77GSE4IO9YVtzkiJFAmRKsxs1DH42jRA-p9eW-FotP1v9wRKGg4v

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: [e-mail] 
 [e-mail] 
--------------------------------------------  -------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: [e-mail] 
 [e-mail] 
--------------------------------------------  -------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  -------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: [phone] 
 e-mail: mailto:[e-mail] 
 [e-mail] 
-------------------------------------------- 
 

Attachment

   -- 19072021_MR_Hemlibra_STASEY data release_en 
      https://ml-eu.globenewswire.com/Resource/Download/dfc9fd0a-31dc-4552-abb3-66aced072c5b

(END) Dow Jones Newswires

July 19, 2021 01:00 ET (05:00 GMT)